Section of Infectious Diseases, Department of Pediatrics, University of Chicago, Chicago, Illinois, United States of America.
PLoS One. 2014 Jan 15;9(1):e85873. doi: 10.1371/journal.pone.0085873. eCollection 2014.
Vancomycin is often the preferred treatment for invasive methicillin-resistant Staphylococcus aureus (MRSA) infection. With the increase in incidence of MRSA infections, the use of vancomycin has increased and, as feared, isolates of vancomycin-resistant Staphylococcus aureus (VRSA) have emerged. VRSA isolates have acquired the entercoccal vanA operon contained on transposon (Tn) 1546 residing on a conjugal plasmid. VraTSR is a vancomycin and β-lactam-inducible three-component regulatory system encoded on the S. aureus chromosome that modulates the cell-wall stress response to cell-wall acting antibiotics. Mutation in vraTSR has shown to increase susceptibility to β-lactams and vancomycin in clinical VISA strains and in recombinant strain COLVA-200 which expresses a plasmid borne vanA operon. To date, the role of VraTSR in vanA operon expression in VRSA has not been demonstrated. In this study, the vraTSR operon was deleted from the first clinical VRSA strain (VRS1) by transduction with phage harvested from a USA300 vraTSR operon deletion strain. The absence of the vraTSR operon and presence of the vanA operon were confirmed in the transductant (VRS1Δvra) by PCR. Broth MIC determinations, demonstrated that the vancomycin MIC of VRS1Δvra (64 µg/ml) decreased by 16-fold compared with VRS1 (1024 µg/ml). The effect of the vraTSR operon deletion on expression of the van gene cluster (vanA, vanX and vanR) was examined by quantitative RT-PCR using relative quantification. A 2-5-fold decreased expression of the vanA operon genes occured in strain VRS1Δvra at stationary growth phase compared with the parent strain, VRS1. Both vancomycin resistance and vancomycin-induced expression of vanA and vanR were restored by complementation with a plasmid harboring the vraTSR operon. These findings demonstrate that expression in S. aureus of the horizontally acquired enterococcal vanA gene cluster is enhanced by the staphylococcal three-component cell wall stress regulatory system VraTSR, that is present in all S. aureus strains.
万古霉素通常是治疗侵袭性耐甲氧西林金黄色葡萄球菌 (MRSA) 感染的首选药物。随着 MRSA 感染发病率的增加,万古霉素的使用量也有所增加,正如人们所担心的那样,耐万古霉素金黄色葡萄球菌 (VRSA) 的分离株已经出现。VRSA 分离株获得了位于转座子 (Tn) 1546 上的肠球菌万古霉素抗性操纵子 (vanA 操纵子),该转座子位于一个可接合的质粒上。VraTSR 是一个位于金黄色葡萄球菌染色体上的万古霉素和β-内酰胺诱导的三组分调节系统,可调节细胞壁对作用于细胞壁的抗生素的应激反应。在临床 VISA 株和表达质粒携带的 vanA 操纵子的重组菌株 COLVA-200 中,vraTSR 的突变显示出对β-内酰胺类药物和万古霉素的敏感性增加。迄今为止,VraTSR 在 VRSA 中 vanA 操纵子表达中的作用尚未得到证实。在这项研究中,通过从 USA300 株 vraTSR 操纵子缺失株中收获噬菌体转导,从第一株临床 VRSA 株 (VRS1) 中缺失了 vraTSR 操纵子。转导子 (VRS1Δvra) 中不存在 vraTSR 操纵子和存在 vanA 操纵子通过 PCR 得到证实。肉汤 MIC 测定表明,与 VRS1 (1024 μg/ml) 相比,VRS1Δvra 的万古霉素 MIC(64 μg/ml)降低了 16 倍。通过相对定量定量 RT-PCR 检测了 vraTSR 操纵子缺失对 van 基因簇 (vanA、vanX 和 vanR) 表达的影响。与亲本菌株 VRS1 相比,在静止生长阶段,菌株 VRS1Δvra 中 vanA 操纵子基因的表达降低了 2-5 倍。通过用携带 vraTSR 操纵子的质粒互补,恢复了万古霉素耐药性和万古霉素诱导的 vanA 和 vanR 表达。这些发现表明,金黄色葡萄球菌中水平获得的肠球菌 vanA 基因簇的表达是由所有金黄色葡萄球菌菌株中存在的金黄色葡萄球菌三组分细胞壁应激调节系统 VraTSR 增强的。